Article | 14.08.2026
Blog and news
topic :
category :
status :
Article | 14.08.2026
How can liver fibrosis be assessed without a biopsy? The role of noninvasive tests and controlled-vibration pulse elastography
Article | 14.08.2026
MASLD vs MASH: what are the differences?
Article | 06.08.2026
Fierce Healthcare: Not All Noninvasive Imaging Technologies Are Evaluated the Same by Payers
Press Release | 16.07.2026
Echosens Shares BlueCross BlueShield of Tennessee Medical Policy Update Clarifying Coverage for FibroScan® and Other Noninvasive Elastography Technologies
Article | 01.07.2026
Appropriate Coding and Billing for FibroScan®
Webinar | 15.06.2026
FibroScan® Guided VCTE® : Best Practice Review and Clinical Insights
Webinar | 15.06.2026
Multidisciplinary management of MASLD–MASH: bridging diabetology and hepatology
Webinar | 15.06.2026
How to Build & Operationalize a Successful Liver Program with FibroScan®
Press Release | 02.06.2026
Echosens Appoints Romain Baujard as Group Chief Executive Officer
White Paper | 17.04.2026
New White Paper – Vibration-Controlled Transient Elastography Explained
Webinar | 14.04.2026
Connecting the Dots: From Metabolic Risk to Liver Disease — A Primary Care Approach
Article | 06.11.2025
Statement on the acceptance by the FDA of Echosens’ Letter of Intent for Drug Development Tool (DDT)
Article | 16.09.2025
A New Era for Liver Care: Prof. Dr. Jörn Schattenberg on the EC Approval of Rezdiffra™ for MASH
Webinar | 26.08.2025